The US Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), the first cell-based gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS). Waskyra is indicated for paediatric patients six months and older and adults with WAS who have a mutation in the WAS gene and for whom haematopoietic stem cell transplantation (HSCT) is […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!